Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00359873 | Esophagus | ESCC | endodermal cell differentiation | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
GO:003296812 | Esophagus | ESCC | positive regulation of transcription elongation from RNA polymerase II promoter | 12/8552 | 13/18723 | 6.18e-04 | 3.32e-03 | 12 |
GO:0045637111 | Esophagus | ESCC | regulation of myeloid cell differentiation | 118/8552 | 210/18723 | 1.35e-03 | 6.43e-03 | 118 |
GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
GO:00481471 | Esophagus | ESCC | negative regulation of fibroblast proliferation | 22/8552 | 30/18723 | 1.98e-03 | 8.90e-03 | 22 |
GO:200004513 | Esophagus | ESCC | regulation of G1/S transition of mitotic cell cycle | 82/8552 | 142/18723 | 2.49e-03 | 1.08e-02 | 82 |
GO:190280613 | Esophagus | ESCC | regulation of cell cycle G1/S phase transition | 95/8552 | 168/18723 | 2.91e-03 | 1.22e-02 | 95 |
GO:007122215 | Esophagus | ESCC | cellular response to lipopolysaccharide | 113/8552 | 209/18723 | 8.79e-03 | 3.10e-02 | 113 |
GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
GO:19033116 | Liver | NAFLD | regulation of mRNA metabolic process | 66/1882 | 288/18723 | 1.06e-10 | 2.96e-08 | 66 |
GO:00165703 | Liver | NAFLD | histone modification | 90/1882 | 463/18723 | 5.74e-10 | 1.28e-07 | 90 |
GO:00316477 | Liver | NAFLD | regulation of protein stability | 61/1882 | 298/18723 | 5.00e-08 | 4.71e-06 | 61 |
GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
GO:00506846 | Liver | NAFLD | regulation of mRNA processing | 33/1882 | 137/18723 | 1.47e-06 | 6.73e-05 | 33 |
GO:00160555 | Liver | NAFLD | Wnt signaling pathway | 74/1882 | 444/18723 | 8.98e-06 | 2.96e-04 | 74 |
GO:01987385 | Liver | NAFLD | cell-cell signaling by wnt | 74/1882 | 446/18723 | 1.05e-05 | 3.33e-04 | 74 |
GO:00226137 | Liver | NAFLD | ribonucleoprotein complex biogenesis | 76/1882 | 463/18723 | 1.19e-05 | 3.67e-04 | 76 |
GO:19033134 | Liver | NAFLD | positive regulation of mRNA metabolic process | 28/1882 | 118/18723 | 1.21e-05 | 3.70e-04 | 28 |
GO:00301115 | Liver | NAFLD | regulation of Wnt signaling pathway | 57/1882 | 328/18723 | 2.79e-05 | 7.46e-04 | 57 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDC73 | SNV | Missense_Mutation | | c.1073G>A | p.Arg358Gln | p.R358Q | Q6P1J9 | protein_coding | deleterious(0.01) | probably_damaging(0.949) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDC73 | SNV | Missense_Mutation | | c.1352N>T | p.Ala451Val | p.A451V | Q6P1J9 | protein_coding | tolerated(0.06) | benign(0.119) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDC73 | SNV | Missense_Mutation | | c.1019N>C | p.Val340Ala | p.V340A | Q6P1J9 | protein_coding | tolerated(0.78) | benign(0.007) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CDC73 | SNV | Missense_Mutation | novel | c.1034N>A | p.Ser345Tyr | p.S345Y | Q6P1J9 | protein_coding | tolerated(0.13) | probably_damaging(0.949) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
CDC73 | SNV | Missense_Mutation | novel | c.947N>T | p.His316Leu | p.H316L | Q6P1J9 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
CDC73 | SNV | Missense_Mutation | | c.1247N>A | p.Gly416Asp | p.G416D | Q6P1J9 | protein_coding | deleterious(0.03) | benign(0.03) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CDC73 | SNV | Missense_Mutation | novel | c.1537N>T | p.Arg513Trp | p.R513W | Q6P1J9 | protein_coding | deleterious(0.02) | possibly_damaging(0.562) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
CDC73 | SNV | Missense_Mutation | novel | c.72N>C | p.Glu24Asp | p.E24D | Q6P1J9 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CDC73 | SNV | Missense_Mutation | | c.921N>G | p.Phe307Leu | p.F307L | Q6P1J9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CDC73 | SNV | Missense_Mutation | rs878855091 | c.787C>T | p.Arg263Cys | p.R263C | Q6P1J9 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |